{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:35:31Z","timestamp":1788978931047,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17pc0101019"],"award-info":[{"award-number":["JP17pc0101019"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023368","name":"Eisai Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.omtn.2023.01.005","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T13:12:04Z","timestamp":1673615524000},"page":"339-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Identification of potent siRNA targeting complement C5 and its robust activity in pre-clinical models of myasthenia gravis and collagen-induced arthritis"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0782-565X","authenticated-orcid":false,"given":"Yoshikazu","family":"Kuboi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Motoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Toritsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Tomimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Soejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2023.01.005_bib1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2023.01.005_bib2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41573-019-0031-6","article-title":"Clinical promise of next-generation complement therapeutics","volume":"18","author":"Mastellos","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2023.01.005_bib3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2023.01.005_bib4","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2012.00368","article-title":"New insights for C5a and C5a receptors in sepsis","volume":"3","author":"Yan","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2023.01.005_bib5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.01.005_bib6","first-page":"555","article-title":"[New complement therapeutics in complement-related diseases]","volume":"71","author":"Wakamiya","year":"2019","journal-title":"Brain Nerve"},{"key":"10.1016\/j.omtn.2023.01.005_bib7","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1681\/ASN.2012020119","article-title":"Endothelium-neutrophil interactions in ANCA-associated diseases","volume":"23","author":"Halbwachs","year":"2012","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.omtn.2023.01.005_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/ki.2013.24","article-title":"Antineutrophil cytoplasm antibody-associated vasculitis: recent developments","volume":"84","author":"Furuta","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.omtn.2023.01.005_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.kint.2019.02.038","article-title":"Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?","volume":"96","author":"Noris","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.omtn.2023.01.005_bib10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/14397595.2016.1193965","article-title":"Differential activation mechanisms of serum C5a in lupus nephritis and neuropsychiatric systemic lupus erythematosus","volume":"27","author":"Sakuma","year":"2017","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.omtn.2023.01.005_bib11","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1681\/ASN.2005040373","article-title":"C5a receptor deficiency attenuates T\u00a0cell function and renal disease in MRLlpr mice","volume":"16","author":"Wenderfer","year":"2005","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.omtn.2023.01.005_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/cei.12338","article-title":"Rapid-onset clinical and mechanistic effects of anti-C5aR treatment in the mouse collagen-induced arthritis model","volume":"177","author":"Andersson","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.omtn.2023.01.005_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00024382-200405000-00002","article-title":"The role of the complement system in ischemia-reperfusion injury","volume":"21","author":"Arumugam","year":"2004","journal-title":"Shock"},{"key":"10.1016\/j.omtn.2023.01.005_bib14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement inhibitor therapy for myasthenia gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2023.01.005_bib15","doi-asserted-by":"crossref","first-page":"577767","DOI":"10.1016\/j.jneuroim.2021.577767","article-title":"Eculizumab treatment for myasthenia gravis subgroups: 2021 update","volume":"362","author":"Jiao","year":"2022","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.omtn.2023.01.005_bib16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/WCO.0000000000000813","article-title":"Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases","volume":"33","author":"Mader","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.omtn.2023.01.005_bib17","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","article-title":"Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model","volume":"131","author":"Halstead","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2023.01.005_bib18","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1097\/TP.0000000000004207","article-title":"Novel complement C5 small-interfering RNA lipid nanoparticle prolongs graft survival in a hypersensitized rat kidney transplant model","volume":"106","author":"Ishigooka","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.omtn.2023.01.005_bib19","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.01.005_bib20","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.01.005_bib21","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.01.005_bib22","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2023.01.005_bib23","doi-asserted-by":"crossref","first-page":"556104","DOI":"10.3389\/fneur.2020.556104","article-title":"Concomitant immunosuppressive therapy use in eculizumab-treated adults with generalized myasthenia gravis during the REGAIN open-label extension study","volume":"11","author":"Nowak","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.omtn.2023.01.005_bib24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.01.005_bib25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nrneph.2014.30","article-title":"Anaemia: mutations in C5 explain eculizumab resistance","volume":"10","author":"Razzak","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.omtn.2023.01.005_bib26","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.01.005_bib27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","article-title":"Complement and its receptors: new insights into human disease","volume":"32","author":"Holers","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omtn.2023.01.005_bib28","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.01.005_bib29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2023.01.005_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2023.01.005_bib31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2023.01.005_bib32","first-page":"333","article-title":"The complement system in liver diseases","volume":"3","author":"Qin","year":"2006","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omtn.2023.01.005_bib33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in siRNA delivery mediated by lipid-based nanoparticles","volume":"154-155","author":"Yonezawa","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2023.01.005_bib34","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.omtn.2023.01.005_bib35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2015.10.024","article-title":"siRNA-lipid nanoparticles with long-term storage stability facilitate potent gene-silencing in\u00a0vivo","volume":"220","author":"Suzuki","year":"2015","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.omtn.2023.01.005_bib36","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ijpharm.2016.06.124","article-title":"Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid","volume":"510","author":"Suzuki","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtn.2023.01.005_bib37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijpharm.2017.01.016","article-title":"Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates","volume":"519","author":"Suzuki","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtn.2023.01.005_bib38","doi-asserted-by":"crossref","first-page":"103104","DOI":"10.1016\/j.autrev.2022.103104","article-title":"Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders","volume":"21","author":"Man\u00e9-Damas","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.omtn.2023.01.005_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.expneurol.2015.02.025","article-title":"Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs","volume":"270","author":"Kusner","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.omtn.2023.01.005_bib40","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2023.01.005_bib41","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","article-title":"Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis","volume":"179","author":"Zhou","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2023.01.005_bib42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ana.21536","article-title":"Novel complement inhibitor limits severity of experimentally myasthenia gravis","volume":"65","author":"Soltys","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2023.01.005_bib43","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/283666a0","article-title":"Immunisation against heterologous type II collagen induces arthritis in mice","volume":"283","author":"Courtenay","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2023.01.005_bib44","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.4049\/jimmunol.140.5.1477","article-title":"Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity","volume":"140","author":"Seki","year":"1988","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2023.01.005_bib45","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1073\/pnas.92.19.8955","article-title":"Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease","volume":"92","author":"Wang","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2023.01.005_bib46","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.4049\/jimmunol.164.8.4340","article-title":"A role for complement in antibody-mediated inflammation: C5-deficient DBA\/1 mice are resistant to collagen-induced arthritis","volume":"164","author":"Wang","year":"2000","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2023.01.005_bib47","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ymthe.2005.11.002","article-title":"Design of noninflammatory synthetic siRNA mediating potent gene silencing in\u00a0vivo","volume":"13","author":"Judge","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.01.005_bib48","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.molimm.2011.05.001","article-title":"Complement deficiency states and associated infections","volume":"48","author":"Skattum","year":"2011","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omtn.2023.01.005_bib49","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.omtn.2023.01.005_bib50","first-page":"121","article-title":"A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome","volume":"70","author":"Westra","year":"2012","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.omtn.2023.01.005_bib51","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.omtm.2019.04.009","article-title":"Investigational RNAi therapeutic targeting C5 is efficacious in pre-clinical models of myasthenia gravis","volume":"13","author":"Kusner","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2023.01.005_bib52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.01.005_bib53","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-Small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.omtn.2023.01.005_bib54","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc\u2013siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2023.01.005_bib55","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/13543784.2021.1897567","article-title":"Zilucoplan: an investigational complement C5 inhibitor for the treatment of acetylcholine receptor autoantibody\u2013positive generalized myasthenia gravis","volume":"30","author":"Howard","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.omtn.2023.01.005_bib56","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtn.2023.01.005_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1074-7613(02)00275-3","article-title":"Arthritis critically dependent on innate immune system players","volume":"16","author":"Ji","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2023.01.005_bib58","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.omtn.2023.01.005_bib59","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1038\/ncomms4862","article-title":"Knockdown and knockout of \u03b21-integrin in hepatocytes impairs liver regeneration through inhibition of growth factor signalling","volume":"5","author":"Speicher","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.01.005_bib60","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.omtn.2021.08.023","article-title":"Irf5 siRNA-loaded biodegradable lipid nanoparticles ameliorate concanavalin A-induced liver injury","volume":"25","author":"Kawase","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2023.01.005_bib61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jim.2009.11.003","article-title":"Preparing serum for functional complement assays","volume":"352","author":"Lachmann","year":"2010","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.omtn.2023.01.005_bib62","doi-asserted-by":"crossref","first-page":"R160","DOI":"10.1186\/ar3119","article-title":"A multiparameter approach to monitor disease activity in collagen-induced arthritis","volume":"12","author":"Seeuws","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.omtn.2023.01.005_bib63","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s10875-012-9839-0","article-title":"Curcumin protects against collagen-induced arthritis via suppression of BAFF production","volume":"33","author":"Huang","year":"2013","journal-title":"J.\u00a0Clin. Immunol."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123000082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123000082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:33:14Z","timestamp":1761874394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253123000082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":63,"alternative-id":["S2162253123000082"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2023.01.005","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of potent siRNA targeting complement C5 and its robust activity in pre-clinical models of myasthenia gravis and collagen-induced arthritis","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2023.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}]}}